Vasculitis

Vasculitis is a condition that involves inflammation in the blood vessels. The condition occurs if your immune system attacks your blood vessels by mistake. This may happen as the result of an infection, a medicine, or another disease or condition. The inflammation can lead to serious problems. Complications depend on which blood vessels, organs, or other body systems are affected. Vasculitis can affect any of the body's blood vessels. These include arteries, veins, and capillaries. Arteries carry blood from your heart to your body's organs. Veins carry blood from your organs and limbs back to your heart. Capillaries connect the small arteries and veins.
What is Vasculitis?

Vasculitis literally means inflammation of blood vessels and includes many different conditions. There are various different causes and types of vasculitis, which lead to specific symptoms and management.

Read More

Overview

Feature Articles

Latest Vasculitis News and Research

Scientists isolate individual cells that cause autoimmune disease

Scientists isolate individual cells that cause autoimmune disease

Rheumatoid arthritis linked to other diseases, finds new study

Rheumatoid arthritis linked to other diseases, finds new study

Study shows ADA2 is a sensitive, specific biomarker for macrophage activation syndrome

Study shows ADA2 is a sensitive, specific biomarker for macrophage activation syndrome

Clinical trial to evaluate efficacy and safety of new treatment for giant cell arteritis

Clinical trial to evaluate efficacy and safety of new treatment for giant cell arteritis

Survey says half of people with rheumatoid disease struggle to pay for treatment

Survey says half of people with rheumatoid disease struggle to pay for treatment

Tiny fat bubbles hold key to rebooting the immune system and calming disease process

Tiny fat bubbles hold key to rebooting the immune system and calming disease process

Researchers identify encephalitis as rare toxicity of immunotherapy treatment

Researchers identify encephalitis as rare toxicity of immunotherapy treatment

Promising methods for early detection and treatment of rheumatoid arthritis

Promising methods for early detection and treatment of rheumatoid arthritis

Radiation-induced vascular damage could be treated with IL-1 inhibitors

Radiation-induced vascular damage could be treated with IL-1 inhibitors

Association found between gene variant and lung disease in the form of systemic vasculitis

Association found between gene variant and lung disease in the form of systemic vasculitis

Researchers reveal promising biomarker for vascular disease relapse

Researchers reveal promising biomarker for vascular disease relapse

Immune checkpoint inhibitors induce rheumatic and musculoskeletal diseases

Immune checkpoint inhibitors induce rheumatic and musculoskeletal diseases

Meta-analysis reveals effective treatment options for urticarial vasculitis

Meta-analysis reveals effective treatment options for urticarial vasculitis

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

FDA approves update to Rituxan label to include information on treatment of rare forms of vasculitis

Health Care Apps and the Empowered Patient

Health Care Apps and the Empowered Patient

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint